Trade Sales

Angle PLC
14 February 2007



For Immediate Release                                           14 February 2007

                                   ANGLE plc

                        Trade sale of Acolyte Biomedica

ANGLE plc ('ANGLE') is pleased to announce that its venture company Acolyte
Biomedica Ltd ('Acolyte') has been sold to 3M Corporation ('3M').

Under the terms of the agreement, 3M will make an initial cash payment to the
vendors of Acolyte on completion plus a further cash payment based on the level
of 3M sales of Acolyte-derived products in the calendar year 2009. ANGLE's share
of the proceeds will be up to £5.6 million consisting of initial cash proceeds
of £0.9 million and a second cash payment of up to £4.7 million. The cash
proceeds will be applied towards the expansion of ANGLE's business through the
development of new ventures using ANGLE's Progeny(R) process. In the year ended
31 December 2006, Acolyte's sales were £0.1 million on which it made a pre-tax
loss of £1.6 million. As at 31 December 2006, Acolyte had net assets of £0.3
million.

ANGLE founded Acolyte in conjunction with the Defence Science and Technology
Laboratories (Dstl), an agency of the Ministry of Defence at Porton Down,
Wiltshire, on whose technology it is based, in 2000. The current shareholder
base includes Porton Capital, Ploughshare Innovations (Dstl's Technology
Transfer arm) and Partnerships UK and the company is chaired by John McKinley.

ANGLE has been actively involved in the management of the business ever since.
Andrew Newland chaired the business for the first two years of its existence and
an ANGLE executive has been on the board ever since its establishment. During
this time, Acolyte has completed three venture capital rounds, undertaken key
product development and launched its first product, the BacLite(R) Rapid MRSA
test which allows hospitals to obtain results within five hours of screening
patients and hospital workers for the presence of MRSA. This compares with three
days to obtain results from conventional screening.

Detection of the MRSA super-bug is the first application of Acolyte's BacLite(R)
technology, which can also be applied to the diagnosis of a wide range of other
serious infections.

Andrew Newland, Chief Executive of ANGLE plc said:
'The development of Acolyte Biomedica from start-up through to trade sale to a
major international company is a major milestone for ANGLE and demonstrates the
strength of ANGLE's Progeny(R) process in generating value. ANGLE's other
portfolio companies are built using the same Progeny(R) process although we have
substantially greater equity stakes in the companies built since our flotation
than in Acolyte at exit.'

For further information:

ANGLE plc                                      01483 295830
Andrew Newland, Chief Executive
John Holden, Director - Ventures Development

Buchanan Communications                        020 7466 5000
Richard Darby, Suzanne Brocks, James Strong

Notes to Editors

ANGLE
Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)
and operates from offices in the UK, the US and the Middle East. Further
information can be found on www.ANGLEplc.com

Acolyte Biomedica Ltd
Acolyte Biomedica Ltd was founded in February 2000 by ANGLE in conjunction with
Dstl and developed under ANGLE's Progeny(R) programme. It is one of eleven such
companies in the ANGLE portfolio at present. Dr Bill Mullen, Acolyte's CEO is a
former ANGLE senior executive. Acolyte signed its first agreement with Dstl
(then DERA) later that year. Acolyte develops, manufactures and markets rapid
microbiology products and has an exclusive global licence to AK Rapid(R)
technology, granted from Dstl for clinical and veterinary use. It has further
developed this ultra sensitive detection technology into a series of commercial
prototype products, which rapidly detect the presence of bacteria and determine
their antibiotic susceptibility direct from clinical samples such as blood. In
January 2006, Acolyte launched a rapid culture based MRSA test, BacLite Rapid,
which can detect the presence or absence of MRSA direct from clinical samples in
less than 5 hours. This is the only available rapid screening test which can
discriminate between live and dead bacteria allowing clinicians to determine the
risk of resistant bacteria spreading in the hospital environment. During the
transaction, the Company was advised by AGI Corporate Finance Ltd of London, UK.
www.acolytebiomedica.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange